Nandalal Santosh, Venkatesan Harshitha, Haridoss Madhumitha, Ramachandran Krithika, Lenin Raji Rajesh
Division of Medical Research, Faculty of Medicine and Health Sciences, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, 603203, India.
Int J Retina Vitreous. 2024 Dec 18;10(1):93. doi: 10.1186/s40942-024-00615-8.
About one-third of individuals with diabetes develop diabetic retinopathy (DR), with one-tenth experiencing vision-threatening conditions such as diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR). Current treatments only show recovery in 50% of cases, and the disease often remains asymptomatic. Therefore, novel early detection methods and new biomarkers are crucial. Our study aims to summarise evidence on the role of altered exosomal regulatory noncoding RNAs in DR, based on human studies. Observational studies delineating the different exosomal noncoding RNAs in DR were searched systematically from inception to June 2024 in PubMed-MEDLINE and SCOPUS databases. Preferred Reporting Items of Systematic Reviews and Meta-analysis (PRISMA) 2020 guidelines was used to conduct this systematic review (Prospero ID: CRD42023406724). We synthesised data from 13 human studies that assessed the expression of exosomal regulatory ncRNAs from individuals with DR. Among the 13 studies, nine focused on miRNA, while three examined lncRNA and one on circRNA. Although no common genes were identified across the studies, the review underscores the critical roles of exosomal noncoding RNAs in the pathogenesis of diabetic retinopathy, highlighting their potential as therapeutic targets. Future studies should aim for a unified approach in terms of sample selection, RNA analysis, and appropriate controls for a comprehension of exosomal expression patterns for early diagnosis of DR.
约三分之一的糖尿病患者会发展为糖尿病视网膜病变(DR),其中十分之一会出现威胁视力的病症,如糖尿病性黄斑水肿(DME)或增殖性糖尿病视网膜病变(PDR)。目前的治疗仅在50%的病例中显示有恢复效果,且该疾病通常无症状。因此,新型早期检测方法和新的生物标志物至关重要。我们的研究旨在基于人体研究总结关于外泌体调节性非编码RNA在DR中作用的证据。从创刊至2024年6月,在PubMed-MEDLINE和SCOPUS数据库中系统检索了描述DR中不同外泌体非编码RNA的观察性研究。使用系统评价和Meta分析的首选报告项目(PRISMA)2020指南进行这项系统评价(国际前瞻性系统评价注册平台标识符:CRD42023406724)。我们综合了13项人体研究的数据,这些研究评估了DR患者外泌体调节性非编码RNA的表达。在这13项研究中,9项聚焦于miRNA,3项研究lncRNA,1项研究circRNA。尽管各项研究未发现共同基因,但该综述强调了外泌体非编码RNA在糖尿病视网膜病变发病机制中的关键作用,突出了它们作为治疗靶点的潜力。未来的研究应在样本选择、RNA分析和适当对照方面采用统一方法,以理解外泌体表达模式用于DR的早期诊断。